· Protium Science to expand CDAO services through collaboration with Patheon

Protium Science, a TiumBio (KRX: 321550. KQ) company specializing in contract development and analysis for biologics, announced that the company has signed a Memorandum of Understanding (MOU) with Patheon, the global CDMO company, to cement their strategic collaboration. Under the memorandum, Protium Science will be in charge of contract development services, and Patheon will be responsible for contract manufacturing services, aiming to provide a higher level of service in biopharmaceutical process development and production.

Both companies plan to establish a close collaborative framework for CDMO (Contract Development and Manufacturing Organization) business based on the accumulated expertise, technology, and trust in their respective fields and to continue their ongoing collaborative partnership.

“The MOU between Protium Science and Patheon will enable Protium Science to provide high-level CDMO services, ranging from process development to analysis and production, and facilitate global contract manufacturing,” said Yongho Ahn, chief executive officer of Protium Science. “We look forward to fulfilling a variety of customer needs together with Patheon,” he added.

Protium Science is a subsidiary of TiumBio, a Kosdaq-listed biopharmaceutical company focused on the discovery and development of novel drugs for patients with rare and incurable diseases. Protium Science provides comprehensive process development services ranging from cell line development for biologics to the entire process development for active pharmaceutical ingredients and finished pharmaceutical products. The company also offers consulting services for the documentation required for clinical trial applications and supplemental requests from regulatory authorities. For GMP manufacturing, Protium Science has established domestic CMO services through MOUs with STGEN Bio, a subsidiary of Dong-A Socio Holdings, and Reyon Pharmaceutical. With the MOU with Patheon, Protium Science is now equipped to provide international CMO services as well.

Since its establishment in 2021, Protium Science has entered into over 210 CDAO contracts as of July of this year, achieving a cumulative order amount exceeding 10 billion won.

Patheon, the CDMO division of Thermo Fisher Scientific, specializes in providing a range of services to help pharmaceutical and biotech companies bring their products from the early development stages through commercial production. These services include drug development, formulation, contract research, manufacturing and supply services.

With a global network of 65 manufacturing facilities across the United States, Europe, Asia, Australia, and more, Patheon possesses expertise and capabilities for the development and manufacturing of active pharmaceutical ingredients and biologics. The company supports the entire process of pharmaceutical development and manufacturing, including services such as cell and gene therapy, virus vectors for vaccine, and GMP plasmid DNA manufacturing, clinical trial solutions, finished pharmaceutical production, packaging, and integrated logistics services.